Thyroid Cancer clinical trials in Michigan

9 actively recruiting thyroid cancer trials at 48 sites across Michigan.

Data from ClinicalTrials.gov · last refreshed 2026-05-25

Phase 3 Recruiting Network

Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

This phase III trial compares the effect of cabozantinib versus combination dabrafenib and trametinib for the treatment of patients with differentiated thyroid cancer that does not respond to treatment (refractory) and which expresses a BR…

Sponsor: ECOG-ACRIN Cancer Research Group

NCT ID: NCT06475989

Sites in Michigan:

MyMichigan Medical Center Gratiot — Alma, Michigan
MyMichigan Medical Center Alpena — Alpena, Michigan
Trinity Health IHA - Obstetrics and Gynecology West Arbor — Ann Arbor, Michigan
Trinity Health Saint Joseph Mercy Hospital Ann Arbor — Ann Arbor, Michigan
University of Michigan Rogel Cancer Center — Ann Arbor, Michigan

View on ClinicalTrials.gov →

Phase 1, Phase 2 Recruiting Industry

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…

Sponsor: Turning Point Therapeutics, Inc.

NCT ID: NCT03093116

Sites in Michigan:

Local Institution - 2105 — Ann Arbor, Michigan
Local Institution - 2111 — Detroit, Michigan
Local Institution - 2140 — Detroit, Michigan

View on ClinicalTrials.gov →

Phase 1, Phase 2 Recruiting Industry

A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation

This is a study to evaluate the safety and potential anti-tumor activity of an investigational agent called ARV-806 in Adults with Advanced Cancer having a specific KRAS mutation. This is an open-label study which means that participants a…

Sponsor: Arvinas Inc.

NCT ID: NCT07023731

Sites in Michigan:

Clinical Trial Site — Grand Rapids, Michigan

View on ClinicalTrials.gov →

Phase 1, Phase 2 Recruiting Academic/Other

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies …

Sponsor: Institut de Recherches Internationales Servier

NCT ID: NCT05786924

Sites in Michigan:

South Texas Accelerated Research Therapeutics (START) Midwest — Grand Rapids, Michigan

View on ClinicalTrials.gov →

Phase 2 Recruiting Academic/Other

Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC

This research is being done to determine the efficacy of selpercatinib to restore radioactive iodine (I-131 NaI) uptake and allow for I-131 treatment in people with RET fusion-positive radioiodine-refractory thyroid cancer. This research s…

Sponsor: Massachusetts General Hospital

NCT ID: NCT05668962

Sites in Michigan:

University of Michigan — Ann Arbor, Michigan

View on ClinicalTrials.gov →

Phase 2 Recruiting Academic/Other

Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer

This study will be a non-randomized pilot trial using Cyclophosphamide and Sirolimus for the treatment of metastatic differentiated thyroid cancer. Patients will be treated with Sirolimus 4 mg, PO, days 1-28 as well as Cyclophosphamide 100…

Sponsor: University of Michigan Rogel Cancer Center

NCT ID: NCT03099356

Sites in Michigan:

University of Michigan Cancer Center — Ann Arbor, Michigan

View on ClinicalTrials.gov →

Phase 1 Recruiting Industry

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) alone or in combination as a potential cancer treatment for adults with advanced solid tumors. The study will be conducted in two par…

Sponsor: Pfizer

NCT ID: NCT05538130

Sites in Michigan:

Brigitte Harris Cancer Pavilion — Detroit, Michigan
Henry Ford Hospital — Detroit, Michigan

View on ClinicalTrials.gov →

Phase 1 Recruiting Industry

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07799933) administered as a single agent and in combination with other study medicines in people with solid tumors. This study is …

Sponsor: Pfizer

NCT ID: NCT05355701

Sites in Michigan:

Brigitte Harris Cancer Pavilion — Detroit, Michigan
Henry Ford Hospital — Detroit, Michigan
Henry Ford Medical Center - Columbus — Novi, Michigan
CT Scan and Echo Only: Henry Ford Medical Center-Plymouth — Plymouth, Michigan

View on ClinicalTrials.gov →

Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology

NCT ID: NCT05334069

Sites in Michigan:

MyMichigan Medical Center Gratiot — Alma, Michigan
MyMichigan Medical Center Alpena — Alpena, Michigan
Trinity Health Saint Joseph Mercy Hospital Ann Arbor — Ann Arbor, Michigan
Bronson Battle Creek — Battle Creek, Michigan
Trinity Health IHA Medical Group Hematology Oncology - Brighton — Brighton, Michigan

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-05-25